Literature DB >> 27521178

How can cardiothoracic and vascular medical devices stay in the market?

Kathie A Wong1, Luke Hodgson1, George Garas2, George Malietzis1, Sheraz Markar1, Christopher Rao1, Ludwig K von Segesser3, Thanos Athanasiou1.   

Abstract

Surgeons, as the consumers, must engage in commercial activity regarding medical devices since it directly has impacts on surgical practice and patient outcomes. Unique features defy traditional economic convention in this specific market partly because consumers do not usually pay directly. Greater involvement with commercial activity means better post-market surveillance of medical devices which leads to improved patient safety. The medical device industry has exhibited astonishing levels of growth and profitability reaching $398 billion on a global scale with new product development focusing on unmet clinical need. The industry has rapidly emerged within the context of an ageing population and a global surge in healthcare spending. But the market remains fragmented. The split of consumer, purchaser and payer leads to clinical need driving demand for new product development. This demand contributes to potentially large profit margins mainly contained by regulatory burden and liability issues. Demographic trends, prevalence of diseases and a huge capacity to absorb technology have sustained near unparalleled growth. To stay in the market, incremental development over the short term is essentially aided by responsiveness to demand. Disruptive product development is now more likely to come from multinational companies, in an increasingly expensive, regulated industry. Understanding healthcare organization can help explain the highly complex process of diffusion of innovations in healthcare that include medical devices. The time has come for surgeons to become actively involved with all aspects of the medical device life cycle including commercial activity and post-market surveillance. This is vital for improving patient care and ensuring patient safety.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Cardiac; Diffusion; Implementation; Industry; Innovation; Technology

Mesh:

Year:  2016        PMID: 27521178     DOI: 10.1093/icvts/ivw257

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  4 in total

Review 1.  Robotics in otorhinolaryngology - head and neck surgery.

Authors:  George Garas; Neil Tolley
Journal:  Ann R Coll Surg Engl       Date:  2018-09       Impact factor: 1.891

Review 2.  Robotics in cardiac surgery.

Authors:  A H Sepehripour; G Garas; T Athanasiou; R Casula
Journal:  Ann R Coll Surg Engl       Date:  2018-09       Impact factor: 1.891

3.  Network analysis of surgical innovation: Measuring value and the virality of diffusion in robotic surgery.

Authors:  George Garas; Isabella Cingolani; Pietro Panzarasa; Ara Darzi; Thanos Athanasiou
Journal:  PLoS One       Date:  2017-08-25       Impact factor: 3.240

Review 4.  Induced Bias Due to Crossover Within Randomized Controlled Trials in Surgical Oncology: A Meta-regression Analysis of Minimally Invasive versus Open Surgery for the Treatment of Gastrointestinal Cancer.

Authors:  George Garas; Sheraz R Markar; George Malietzis; Hutan Ashrafian; George B Hanna; Emmanouil Zacharakis; Long R Jiao; Athanassios Argiris; Ara Darzi; Thanos Athanasiou
Journal:  Ann Surg Oncol       Date:  2017-11-06       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.